Published in Tissue Antigens on August 01, 2000
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol (2012) 0.93
Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol (2010) 0.84
Extended O-GlcNAc on HLA Class-I-Bound Peptides. J Am Chem Soc (2015) 0.82
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J Immunol (1985) 7.90
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature (1990) 6.23
Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med (1998) 5.78
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 5.08
DsrA RNA regulates translation of RpoS message by an anti-antisense mechanism, independent of its action as an antisilencer of transcription. Proc Natl Acad Sci U S A (1998) 4.99
Glycosylation and the immune system. Science (2001) 4.39
Defining a bacteriophage T4 late promoter: absence of a "-35" region. Cell (1984) 4.16
Assembly of MHC class I molecules analyzed in vitro. Cell (1990) 3.77
Packaging specific segments of the Salmonella chromosome with locked-in Mud-P22 prophages. Genetics (1988) 3.33
Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature (1990) 3.32
Efficient translation of the RpoS sigma factor in Salmonella typhimurium requires host factor I, an RNA-binding protein encoded by the hfq gene. J Bacteriol (1996) 3.04
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Exact prediction of a natural T cell epitope. Eur J Immunol (1991) 2.90
Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med (1991) 2.48
Mutations that increase expression of the rpoS gene and decrease its dependence on hfq function in Salmonella typhimurium. J Bacteriol (1997) 2.36
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29
A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. J Antimicrob Chemother (1992) 2.28
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS (1999) 2.23
Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature (1992) 2.12
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res (1996) 1.93
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol (1999) 1.92
Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science (1990) 1.88
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
NIDDM in the elderly. Diabetes Care (1996) 1.84
Evaluation of a 2% chlorhexidine gluconate in 70% isopropyl alcohol skin disinfectant. J Hosp Infect (2005) 1.78
Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci U S A (1993) 1.77
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
On the nature of peptides involved in T cell alloreactivity. J Exp Med (1991) 1.75
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A (1998) 1.72
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med (2004) 1.71
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 1.67
Two new proteases in the MHC class I processing pathway. Nat Immunol (2000) 1.63
Phosphorylation and metabolism of the transforming protein of Rous sarcoma virus. J Virol (1982) 1.60
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol (2000) 1.59
Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics (1994) 1.58
Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem (1998) 1.57
The genes required for heme synthesis in Salmonella typhimurium include those encoding alternative functions for aerobic and anaerobic coproporphyrinogen oxidation. J Bacteriol (1992) 1.56
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature (1984) 1.54
Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med (2000) 1.54
The peptide binding motif of the disease associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule. Eur J Immunol (1996) 1.53
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol (2000) 1.53
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood (1999) 1.52
Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol (1991) 1.51
The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur J Immunol (1991) 1.49
Limit of T cell tolerance to self proteins by peptide presentation. Science (1990) 1.49
IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol (2001) 1.49
Plasmodium falciparum strains from Papua New Guinea: culture characteristics and drug sensitivity. Southeast Asian J Trop Med Public Health (1980) 1.46
Conditional stability of the HemA protein (glutamyl-tRNA reductase) regulates heme biosynthesis in Salmonella typhimurium. J Bacteriol (1999) 1.46
Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature (1990) 1.45
PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics (2001) 1.44
Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database. Clin Oncol (R Coll Radiol) (2008) 1.44
An algorithm for the prediction of proteasomal cleavages. J Mol Biol (2000) 1.43
Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut (2009) 1.43
Regulation of epidermin biosynthetic genes by EpiQ. Mol Microbiol (1993) 1.42
The biologic and social consequences of perinatal cocaine use in an inner-city population: results of an anonymous cross-sectional study. Am J Obstet Gynecol (1991) 1.42
Candida infective endocarditis. Eur J Clin Microbiol Infect Dis (2008) 1.41
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. J Biol Chem (1994) 1.40
Biosynthesis of the lantibiotic Pep5. Isolation and characterization of a prepeptide containing dehydroamino acids. Eur J Biochem (1990) 1.40
Antibiotic prophylaxis for full-face laser resurfacing: is it necessary? Arch Dermatol (2001) 1.39
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J Exp Med (1995) 1.37
Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology (2001) 1.34
Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol (2001) 1.34
Several HLA alleles share overlapping peptide specificities. J Immunol (1995) 1.33
Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol (1994) 1.32
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol (1999) 1.31
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect (2002) 1.31
Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med (1994) 1.30
Purification of mature schizonts of Plasmodium falciparum on colloidal silica gradients. Bull World Health Organ (1982) 1.30
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ (2006) 1.30
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res (1997) 1.29
The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol (1998) 1.28
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer (1997) 1.28
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Promoter substitution and deletion analysis of upstream region required for rpoS translational regulation. J Bacteriol (1998) 1.25
Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol (2001) 1.25
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med (1995) 1.25
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24